Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

Miner, P

doi:10.1016/j.amjgastroenterol.2003.09.053

Cited by 96 publications

(151 citation statements)

References 0 publications

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…A more favorable metabolism of esomeprazole leads to an increase in plasma AUC (esomeprazole, 20 mg/day, shows an AUC which is almost doubled compared to omeprazole at the same dosage) [62], which in turn corresponds to increased amounts of the drug reaching the pumps in the gastric parietal cells. Indeed, esomeprazole 20 mg/day exerts a superior intragastric pH control (pH ≥4) compared to the same dose of omeprazole at 8, 12, and 16 h in patients with GERD [59]. As a consequence, esomeprazole has a superior bioavailability compared to omeprazole, reaching a value of 90% (the highest value among PPIs) with 40 mg/day [7, 63, 64].…”

Section: Pharmacology Of Esomeprazolementioning

confidence: 99%

See 1 more Smart Citation

Potential Options to Optimize Therapy of Gastroesophageal Reflux Disease with Proton Pump Inhibitors

et al. 2007

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are antisecretory agents that are widely used in the short- and long-term management of gastroesophageal reflux disease (GERD) to relieve symptoms, heal esophagitis, and prevent complications, such as strictures and Barrett’s esophagus. The total healthcare costs of GERD are high, especially for maintenance treatment. Therefore, the choice of cost-effective therapeutic options is an ineluctable challenge for public health authorities, third-party payers, and patients. In some European Union countries, a recent trend of public health authorities is to promote the choice of less expensive PPIs, regardless of their antisecretory potency – this in spite of the evidence that newer PPIs provide superior symptom relief and esophageal erosion healing compared to earlier drugs. Several large clinical trials have demonstrated the superiority of esomeprazole over other PPIs at standard doses for both initial and continuous maintenance therapy in patients with moderate/severe erosive esophagitis. The non-erosive GERD poses a major challenge as this condition appears more frequently to be less responsive to PPIs. The use of PPIs with the strongest antisecretory properties might reveal to be more adequate and cost-effective, particularly for this indication.

show abstract

Section: Pharmacology Of Esomeprazolementioning

confidence: 99%

“…Based on current clinical evidence, which is partly sustained by the weight of numbers (see above), esomeprazole is the most efficacious antisecretory agent [59] for the treatment of GERD. As a consequence, not all PPIs are equal.…”

Section: Are Ppis All Equal?mentioning

confidence: 99%

Potential Options to Optimize Therapy of Gastroesophageal Reflux Disease with Proton Pump Inhibitors

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Studies have already shown that oral esomeprazole 40 mg is the first PPI to provide greater intragastric acid control than all other PPIs [3, 4]. Furthermore, intravenous esomeprazole has previously been shown to provide a similar level of acid control to oral administration in healthy subjects when given as a 30-min intravenous infusion [11].…”

Section: Discussionmentioning

confidence: 99%

“…Esomeprazole is the first oral proton pump inhibitor (PPI) to provide a more profound and longer lasting inhibition of gastric acid secretion during a 24-hour period than all other PPIs [3, 4]. Clinical studies comparing esomeprazole with omeprazole and lansoprazole given in the doses recommended for the healing of erosive esophagitis show that oral esomeprazole demonstrates greater efficacy for the healing of erosive esophagitis and resolution of heartburn [5, 6, 7].…”

Section: Introductionmentioning

confidence: 99%

Esomeprazole 40 mg Administered Intravenously Has Similar Safety and Efficacy Profiles to the Oral Formulation in Patients with Erosive Esophagitis

Schneider

Rensburg²,

Schmidt³

et al. 2004

Digestion

View full text Add to dashboard Cite

Background/Aims: An intravenous formulation of esomeprazole has been developed for use in patients where oral administration is not appropriate. This study evaluated safety after 1 and 4 weeks, and efficacy after 4 weeks’ esomeprazole 40 mg once daily treatment, administered via an intravenous injection, intravenous infusion or orally, in patients with erosive esophagitis. Methods: In this double-blind, multi-centre study, patients with endoscopically confirmed erosive esophagitis (Los Angeles grade A–D) were randomized to receive 1 week’s treatment of esomeprazole 40 mg once daily, via a 3-min injection, a 30-min infusion or orally, followed by 3 weeks of open treatment with oral esomeprazole 40 mg once daily. Safety variables were evaluated following 1 and 4 weeks’ esomeprazole treatment. Healing rates at 4 weeks were estimated. Results: Intravenous and oral esomeprazole were equally well tolerated during the first week, and after 4 weeks’ treatment. The 3 treatment groups showed similar levels of healing following 4 weeks’ treatment with esomeprazole (injection + oral: 79.7%; infusion + oral: 80.2%; oral alone: 82.6%). Conclusions: Esomeprazole 40 mg administered via an intravenous injection, intravenous infusion or orally administered for 1 week, followed by 3 weeks of oral dosing, is well tolerated and provides effective healing of erosive esophagitis.

show abstract

“…Overall, there was no difference between rabeprazole 20 mg and esomeprazole 40 mg with respect to effects on intragastric pH over the entire 24-hour period [51]. In one additional study that compared gastric acid control on day 5 following standard doses of esomeprazole (40 mg), rabeprazole (20 mg), lansoprazole (30 mg), pantoprazole (40 mg), and omeprazole (20 mg), esomeprazole maintained intragastric pH >4.0 for a mean of 14.0 h, while rabeprazole maintained intragastric pH >4 for 12.1 h. However, this study did not contain data on nocturnal acid control [52]. …”

Section: Introductionmentioning

confidence: 99%

Therapeutic Options in the Treatment of Nighttime Gastroesophageal Reflux

Orr

2005

Digestion

View full text Add to dashboard Cite

Approximately three quarters of individuals who suffer from gastroesophageal reflux disease (GERD) experience its symptoms at night. Nighttime GERD symptoms disturb sleep and diminish quality of life more so than daytime symptoms. Nighttime gastroesophageal reflux is common in individuals with respiratory disorders such as sleep apnea and asthma, and may affect the severity and the frequency of these disorders. The treatments of choice for nighttime GERD symptoms are proton pump inhibitors (PPIs) due to their efficacy in relieving day- and nighttime GERD symptoms and controlling acid secretion. The onset of action, degree of acid suppression, and duration of effect of PPIs have important implications for the use of these therapies in clinical practice. PPIs that exhibit rapid and prolonged control of acid secretion may be particularly useful for treating nighttime GERD symptoms.

show abstract

Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

Abstract: Esomeprazole at the standard dose of 40 mg once daily provided more effective control of gastric acid at steady state than standard doses of lansoprazole, omeprazole, pantoprazole, and rabeprazole in patients with symptoms of gastroesophageal reflux disease.

Cited by 96 publications

References 0 publications

Potential Options to Optimize Therapy of Gastroesophageal Reflux Disease with Proton Pump Inhibitors

Potential Options to Optimize Therapy of Gastroesophageal Reflux Disease with Proton Pump Inhibitors

Esomeprazole 40 mg Administered Intravenously Has Similar Safety and Efficacy Profiles to the Oral Formulation in Patients with Erosive Esophagitis

Therapeutic Options in the Treatment of Nighttime Gastroesophageal Reflux

Contact Info

Product

Resources

About